Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting

Benzinga · 1d ago

https://www.sec.gov/Archives/edgar/data/34956/000119312526417939/d139658dex991.htm